• Filing Date: 2021-04-16
  • Form Type: 10-K/A
  • Description: Annual report (Amendment)
v3.21.1
E. STOCKHOLDERS' EQUITY (Details 4) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Number of options outstanding, ending 451,148  
2016 Stock Incentive Plan    
Number of options outstanding, beginning 52,500 50,000
Number of options granted 341,000 2,500
Number of options outstanding, ending 393,500 52,500
Weighted average exercise price outstanding, beginning $ 5.89 $ 6.10
Weighted average exercise price granted 1.18 1.72
Weighted average exercise price outstanding, ending $ 1.81 $ 5.89
Aggregate intrinsic value [1] $ 233,380  
1999 Amended Stock Plan    
Number of options outstanding, beginning 191,706 191,735
Number of options cancelled (134,058) (29)
Number of options outstanding, ending 57,648 191,706
Weighted average exercise price outstanding, beginning $ 93.40 $ 93.72
Weighted average exercise price cancelled 113.64 2,203.00
Weighted average exercise price outstanding, ending $ 46.34 $ 93.40
Aggregate intrinsic value [1] $ 0  
[1] Amount represents the difference between the exercise price and $1.86, the closing price of Tenax Therapeutics' stock on December 31, 2020, as reported on the Nasdaq Capital Market, for all in-the-money options outstanding.